Clinical trials: Dementia, Alzheimer's Type
Dementia, Alzheimer Disease
Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid
The early detection of a preclinical AD or early stage of AD with amyloid imaging could improve the diagnosis and provide knowledge for better therapeutical approach by combining the best of imaging: structural MR sequences and…
- Trial name
- NCT02343757
- Testing
- PET/MRI
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University Hospitals Cleveland Medical Center
Dementia Alzheimers
Blood-based Biomarkers for Diagnosis of Alzheimer's
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET).
- Trial name
- NCT05187819
- Testing
- predictive value of a blood test
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Helse Stavanger HF
Alzheimer s Disease, Prodromal Alzheimer's Disease
Neuroprotective Effects of Oleanolic Acid and Erythrodiol in Prodromal Alzheimer's Disease
Alzheimer's disease begins many years before memory problems become obvious. People in the early ("prodromal") stage have memory complaints but are still independent in daily life.
- Trial name
- NEUROLEA (NCT07847944)
- Testing
- Oleanolic acid-enriched olive oil, Pomace olive oil, Commercial olive oil 0.4 degrees
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Spanish National Research Council
Cerebrovascular Disorders, Brain Tumours
Environmental Pollutants and Neurological Disorders
Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including…
- Conditions
- Cerebrovascular Disorders, Brain Tumours, Alzheimer Dementia
- Trial name
- CLEAN (NCT07140601)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Cognition Disorder, Alzheimer Disease
Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856
This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy…
- Trial name
- NCT05783830
- Testing
- ACD856
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and…
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease
- Trial name
- ACIST (NCT03724136)
- Testing
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 100 people
- Sponsor
- MD Stem Cells
Dementia, Alzheimer Disease
EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery
EPIC II (Early-Stage Partners in Care) is a research project designed to assist people with early-stage memory loss and their care partners by providing early-stage related education and skill-training sessions, held via Zoom…
- Conditions
- Dementia, Alzheimer Disease, Memory Loss
- Trial name
- NCT03144921
- Testing
- psychoeducational skills training intervention
- Where
- United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Arizona State University
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
- Trial name
- NCT07422857
- Testing
- [18F]-APN-1607
- Where
- 2 sites in China
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Alzheimer's Disease, Huntington's Disease
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects.
- Trial name
- NCT00827034
- Testing
- Warfarin, Dimebon
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dementia, Dementia, Mild
Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged People
We hypothesize that the antioxidant and cytoprotective functions of vitamin E combined with the cortisol-lowering effect of chocolate polyphenols and physical activity may help prevent the age-dependent decline of mitochondrial…
- Conditions
- Dementia, Dementia, Mild, Dementia Moderate, Dementia Senile
- Trial name
- Choko-AGE (NCT05343611)
- Testing
- Combination of High Protein Diet and Physical Exercise protocol, HPP Choko, HPP/VE Choko
- Where
- 4 sites in Italy
- Volunteers
- 102 people
- Sponsor
- Massimo Venturelli, PhD
Agitation Associated With Dementia of the Alzheimer's Type
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication, and to investigate the…
- Trial name
- NCT03620981
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 410 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Alzheimer Disease
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
- Trial name
- NCT02337907
- Testing
- BI 409306, Donepezil
- Where
- 60 sites in United States, Austria and 9 more
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease and Related Dementias
Promoting Positive Care Interactions (PPCI) in Assisted Living
The overall aim of this study is to pilot test Promoting Positive Care Interactions (PPCI) with the goal of establishing a feasible and culturally responsive approach to optimize care interactions between staff (nursing…
- Trial name
- PPCI (NCT05618834)
- Testing
- Promoting Positive Care Interactions (PPCI), PPCI-Staff Education Only (EO)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Penn State University
Hepatitis C
C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
Today's mobile devices (especially smartphones) are powerful ways to communicate new information to medical researchers. For this study, researchers at Boston Children's Hospital are asking people with hepatitis C to make use of…
- Trial name
- CTracker (NCT02568540)
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Boston Children's Hospital
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Alzheimer Disease, Mild Cognitive Impairment
Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
Participants enrolled at the Alzheimer's Disease Research Center (ADRC) at Wake Forest School of Medicine will be invited to take part in this study.
- Trial name
- NCT03089827
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Alzheimer's Disease
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the tolerability and safety of repeated subcutaneous injection of a single dose of AFFITOPE AD02 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00633841
- Testing
- AFFITOPE AD02
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Affiris AG
Alzheimer´s Disease
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers…
- Trial name
- NCT01125683
- Testing
- AZD1446, Donepezil
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Alzheimer's Disease and Related Dementia
Alzheimer's Disease and Related Dementias (ADRD) Prevalence in American Samoa
The goal of this study is to learn about ADRD prevalence within the Samoan population. Participants will be administered a series of cognitive assessments to determine cognitive status and a population-based prevalence of Mild…
- Trial name
- NCT05924529
- Where
- 2 sites in American Samoa
- Volunteers
- 1,098 people
- Sponsor
- American Samoa Community Cancer Coalition
Alzheimer Disease
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
The primary objectives of this study are to characterize [18F]molecular neuroimaging (MNI)-1020, a positron emission tomography (PET) radioligand for imaging tau pathology, to visually and quantitatively assess and compare brain…
- Trial name
- NCT03239561
- Testing
- [18F]MNI-1020
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.